HSP90B1 and cancer: They showed in vitro with another resorcinol inhibitor (binding affinity of 0.54 μmol/L with GRP94 and a 73-fold selectivity towards other HSP90s) that the selective inhibition of GRP94 could decrease migratory abilities of cancer cells and thus be really useful in aggressive cancers[78].